Bullet Points to explain something important for people on fingolimod

Willis M, Pearson O, Illes Z, Sejbaek T, Nielsen C, Duddy M, Petheram K, van Munster C, Killestein J, Malmeström C, Tallantyre E, Robertson N. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2):e320.



Yesterday the "Headmaster" complained my post was too complicated.

http://multiple-sclerosis-research.blogspot.com/2017/01/fingolimod-blocking-alemtuzumab-action.html

So maybe we should just do highlights for the people that like their info in sound bites









    


            However, where is the analysis, explanation?  What do you think?


This rebound will not occur in every body. In this study
there were 36 six people, who had used fingolimod before alemtuzumab and the disease activity was seen in 9 people i.e. 25%. Remember, alemtuzumab is not infallible and relapse (4% in the cardiff cohort) in the first year occurs.

Of these people 8/9 were disease free after the second set of infusions

Labels: ,